Publications in collaboration with researchers from University of Texas Health Science Center at San Antonio (1)

2022

  1. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 2